Developer docs
API playgroundTry for free, no card

Search company profiles

NuvOx Therapeutics

Full company profile

uuid0002fux

Namestring
NuvOx Therapeutics
Legal namestring
NuvOx Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

NuvOx Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company headquartered in Tucson, Arizona, that operates its pharmaceutical activities through a wholly owned subsidiary, NuvOx Pharma, LLC. The company develops NanO2, an intravenous emulsion of dodecafluoropentane (DDFPe) — a perfluorocarbon designed to transport oxygen from the lungs to the blood and from the blood to hypoxic tissues, with the explicit objective of reversing tissue hypoxia across cancer, stroke, respiratory distress, hemorrhagic shock, traumatic brain injury, myocardial infarction and sickle cell anemia. The platform has generated safety data in approximately 2,000 subjects across 7+ indications, holds FDA Orphan Drug Designation for glioblastoma and sickle cell anemia, and is protected by 11 patent families covering 11 issued US patents and 31 foreign equivalents, including US Patent 11,857,627 (January 2024) which broadly claims fractionated radiotherapy and chemotherapy with an oxygen therapeutic.

The company's pipeline is currently organized around three active clinical programs: RESTORE, a US-based Phase IIb in 87 newly diagnosed glioblastoma patients combining NanO2 with radiation and temozolomide; REBORN, an FDA-authorized Phase II in 66 recurrent high-grade glioma patients combining NanO2 with bevacizumab, lomustine and radiation; EXTEND, a dose-escalation Phase Ib and Phase II program in respiratory distress/ARDS partially funded by BARDA and authorized in Canada; and NOVEL, a UK-led Phase IIb in approximately 150 large-vessel-occlusion stroke patients funded by the UK EME Program. Preclinical and translational work extends the platform into triple-negative breast cancer (George Washington University collaboration), spinal cord injury (US Department of Veterans Affairs collaboration), and acute myocardial infarction (FDA IND received March 2025).

NuvOx is pre-revenue: NanO2 is not approved for general medical use and the company is funded through a mix of non-dilutive government grants (NIH NINDS $900K in April 2023, NCI SBIR ~$2M in November 2025, BARDA contract 75A50123C00034, UK EME Program support for NOVEL, Health Canada and MHRA authorizations) and an oversubscribed ~$7 million convertible notes round closed in September 2023 with a syndicate including Keiretsu Capital, MEDA Angels, New World Angels, NO/LA Angel Network, Pasadena Angels and TCA Venture Group. Leadership is anchored by co-founders Dr. Evan Unger (Executive Chairman, recognized with the 2024 Harry Fischer Award for Excellence in Contrast Media Research) and Dr. Jennifer LH Johnson (COO), with Rong Wang as President and CEO and Wilson W. Cheung, CPA, joining as an Independent Board Member in September 2025.

Short descriptiontext

NuvOx Therapeutics is a privately held, clinical-stage biopharmaceutical company developing NanO2 (DDFPe), an intravenous perfluorocarbon oxygen therapeutic designed to reverse tissue hypoxia in glioblastoma, stroke, respiratory distress, myocardial infarction, sickle cell anemia and related indications, currently advancing multiple Phase Ib/IIb trials funded by grants and convertible notes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTucson, United States
HQ citystring
Tucson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oxygen therapeutics, perfluorocarbon emulsion, tissue hypoxia treatment, radiosensitizer therapy, clinical stage biopharmaceutical
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oxygen Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Convertible notes financing
TypeOne Time License
Description

Pre-revenue clinical-stage company; in 2023 closed an oversubscribed convertible notes round raising approximately $7 million, exceeding an initial $5 million goal, to fund Phase IIb and Phase Ib trials.

pr.com
2Exempt securities offering (Form D)
TypeOne Time License
Description

Filing of SEC Form D indicating an exempt securities offering valued at $5 million, with $1,050,000 already sold; reflects private placement capital raise typical of pre-commercial biotech.

sec.gov
3Government and non-dilutive grant funding
TypeLicensing Royalties
Description

Operations funded largely through grants: $900,000 NIH NINDS grant for SPAN stroke network; approximately $2 million NCI SBIR Direct-to-Phase II grant (with FYR Bio); BARDA contract number 75A50123C00034 (EXTEND respiratory distress trial); UK Efficacy and Mechanism Evaluation (EME) Program funding the NOVEL Phase IIb stroke trial. NanO2 is under clinical investigation and not yet approved for general medical use, so there is no product revenue.

nuvoxpharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NanO₂ (NanO₂™)
Description

Lead investigational oxygen therapeutic product candidate of NuvOx; dodecafluoropentane emulsion (DDFPe) designed to enhance oxygen delivery from lungs to blood and from blood to hypoxic tissue. Tested in 7+ indications with safety data in approximately 2,000 subjects.

nuvoxtherapeutics.com
Core offering1 text field

NuvOx Therapeutics is developing NanO2 (dodecafluoropentane emulsion / DDFPe), a first-in-class intravenously administered perfluorocarbon-based oxygen therapeutic intended to reverse tissue hypoxia. The same active ingredient is being investigated across multiple indications including glioblastoma, acute ischemic stroke, respiratory distress/ARDS, acute myocardial infarction, sickle cell anemia, hemorrhagic shock, traumatic brain injury, and spinal cord injury. The product is currently in clinical development (Phase Ib through Phase IIb) and is not yet approved for general medical use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Preclinical stroke: 71%–87% mean reduction in infarct volumes (rabbit model)
+7 more records
Product and service1 record
1NanO2 (DDFPe / dodecafluoropentane emulsion)
CategoryInvestigational oxygen therapeutic platform drug
Description

First-in-class, investigational, intravenously administered perfluorocarbon-based oxygen therapeutic designed to improve the flow of oxygen from lungs to blood and from blood to tissue, reversing tissue hypoxia. Tested in 7+ indications with safety data in approximately 2,000 subjects. Currently under clinical investigation and not yet approved for general medical use.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

NuvOx entered into a research collaboration agreement with the Department of Veteran Affairs to investigate NanO2 in animal models of spinal cord injury. Project led by Dr. Prodip Bose (Director, MRI/PET, and Translational Neurotrauma Rehabilitation Laboratory, Malcom Randall VA Medical Center, North Florida/South Georgia VA Health System).

2George Washington University (Dr. Pavani Chalasani)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Researchers at the GW University Cancer Center, in collaboration with NuvOx, have demonstrated that NanO2 boosts immunotherapy response in Triple Negative Breast Cancer; two abstracts accepted at prestigious conventions in November 2025.

nuvoxtherapeutics.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

FYR Bio and NuvOx Therapeutics are collaborating on liquid-biopsy integration into NuvOx's Phase IIb glioblastoma trial. The partnership is supported by a nearly $2 million Direct-to-Phase II SBIR grant from the US National Cancer Institute (announced September 26, 2025; press release November 19, 2025) to identify biomarkers of glioblastoma progression and treatment response using FYR's EV-based liquid biopsy technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Sunil Krishnan serves as lead Principal Investigator of the REBORN Phase II trial (Radiation Enhancement with Bevacizumab, Lomustine, Oxygen Replenishment, and NanO2 [DDFPe] in Recurrent Gliomas) for recurrent high-grade gliomas, FDA-authorized March 4, 2026.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Site where the first FDA-authorized single-patient Expanded Access treatment of NanO2 for newly diagnosed glioblastoma was administered by Dr. Michael Badruddoja and Dr. Matthew McFarlane on March 10, 2026. Center for Neurosciences is Southern Arizona's largest and longest-standing neuroscience medical practice.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Covenant Health is one of Canada's largest Catholic healthcare organizations. Grey Nuns Community Hospital is the EXTEND-1b trial site with Dr. Senaratne as Principal Investigator; enrolled 6 patients per cohort and observed statistically significant improvement in arterial oxygenation.

Strategic tierCoreTypeOthers
Description

Health Canada authorized the EXTEND Phase Ib respiratory distress trial (June 30, 2024) and the subsequent Phase II trial in moderate-to-severe respiratory distress.

Strategic tierCoreTypeOthers
Description

UK MHRA approved NuvOx to commence the Phase IIb NOVEL stroke trial (announced January 21, 2025).

Strategic tierMinorTypeGTM or Marketing Partner
Description

NuvOx Therapeutics executives participated as external biotech industry presenters at the Second Annual Research Week (April 29 – May 5, 2026), which drew a record 793 total attendees.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Diffusion Pharmaceuticals
TypeDirect peer
Description

Developed trans sodium crocetinate (TSC), an oxygen diffusion enhancer targeting the same hypoxia-driven indications as NanO2 including glioblastoma, stroke, and respiratory distress. NuvOx is widely cited as the most effective of 74 clinical-stage oxygen therapeutic compounds, positioning Diffusion as the most directly comparable peer in the oxygen therapeutic category.

TypeDirect peer
Description

Clinical-stage company developing therapies for cardiopulmonary conditions, including hypoxemic respiratory failure and pulmonary hypertension. Overlaps with NuvOx's EXTEND respiratory distress/ARDS program on oxygen delivery and hypoxia-related cardiopulmonary indications.

3Athersys
TypeDirect peer
Description

Developed MultiStem cell therapy for stroke and ARDS — two of NuvOx's lead indications. Comparable in clinical stage, multi-indication positioning, and reliance on government/academic collaborations to advance pivotal trials.

TypeEmerging player
Description

Clinical-stage oncology company developing paxalisib for glioblastoma. Competes for the same GBM patients, investigators, and clinical sites as NuvOx's RESTORE and REBORN trials.

TypeEmerging player
Description

Clinical-stage company developing berubicin for recurrent glioblastoma. Directly comparable in trial design (recurrent high-grade glioma) and patient population to NuvOx's REBORN trial.

TypeEmerging player
Description

Clinical-stage oncology company developing WP1066 and other hypoxia- and immune-modulating compounds. Comparable in targeting tumor microenvironment and the same grant-driven, investigator-collaborative development model.

TypeEmerging player
Description

Clinical-stage company developing encapsulated cell therapies for solid tumors including pancreatic cancer. Comparable in pre-revenue, clinical-stage oncology positioning and reliance on academic/clinical collaborations.

TypeBroad incumbent
Description

Commercial-stage medical device company with FDA-approved Tumor Treating Fields (Optune) for newly diagnosed and recurrent glioblastoma. Represents the established standard-of-care alternative for the lead indication of NuvOx's RESTORE trial.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Manufactures lomustine (Gleostine), a chemotherapy backbone in NuvOx's REBORN trial for recurrent high-grade glioma. As a large oncology incumbent, Bristol-Myers Squibb is a potential strategic acquirer or combination partner.

TypeBroad incumbent
Description

Commercial-stage company specializing in stroke intervention devices (thrombectomy, aspiration). Represents the established mechanical standard of care in large vessel occlusion stroke, which NanO2 is positioned to complement in the NOVEL Phase IIb trial.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds23 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NuvOx Therapeutics

Oxygen Therapeuticsnuvoxtherapeutics.com

NuvOx Therapeutics is a privately held, clinical-stage biopharmaceutical company developing NanO2 (DDFPe), an intravenous perfluorocarbon oxygen therapeutic designed to reverse tissue hypoxia in glioblastoma, stroke, respiratory distress, myocardial infarction, sickle cell anemia and related indications, currently advancing multiple Phase Ib/IIb trials funded by grants and convertible notes.

What NuvOx Therapeutics does

NuvOx Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company headquartered in Tucson, Arizona, that operates its pharmaceutical activities through a wholly owned subsidiary, NuvOx Pharma, LLC. The company develops NanO2, an intravenous emulsion of dodecafluoropentane (DDFPe) — a perfluorocarbon designed to transport oxygen from the lungs to the blood and from the blood to hypoxic tissues, with the explicit objective of reversing tissue hypoxia across cancer, stroke, respiratory distress, hemorrhagic shock, traumatic brain injury, myocardial infarction and sickle cell anemia. The platform has generated safety data in approximately 2,000 subjects across 7+ indications, holds FDA Orphan Drug Designation for glioblastoma and sickle cell anemia, and is protected by 11 patent families covering 11 issued US patents and 31 foreign equivalents, including US Patent 11,857,627 (January 2024) which broadly claims fractionated radiotherapy and chemotherapy with an oxygen therapeutic.

The company's pipeline is currently organized around three active clinical programs: RESTORE, a US-based Phase IIb in 87 newly diagnosed glioblastoma patients combining NanO2 with radiation and temozolomide; REBORN, an FDA-authorized Phase II in 66 recurrent high-grade glioma patients combining NanO2 with bevacizumab, lomustine and radiation; EXTEND, a dose-escalation Phase Ib and Phase II program in respiratory distress/ARDS partially funded by BARDA and authorized in Canada; and NOVEL, a UK-led Phase IIb in approximately 150 large-vessel-occlusion stroke patients funded by the UK EME Program. Preclinical and translational work extends the platform into triple-negative breast cancer (George Washington University collaboration), spinal cord injury (US Department of Veterans Affairs collaboration), and acute myocardial infarction (FDA IND received March 2025).

NuvOx is pre-revenue: NanO2 is not approved for general medical use and the company is funded through a mix of non-dilutive government grants (NIH NINDS $900K in April 2023, NCI SBIR ~$2M in November 2025, BARDA contract 75A50123C00034, UK EME Program support for NOVEL, Health Canada and MHRA authorizations) and an oversubscribed ~$7 million convertible notes round closed in September 2023 with a syndicate including Keiretsu Capital, MEDA Angels, New World Angels, NO/LA Angel Network, Pasadena Angels and TCA Venture Group. Leadership is anchored by co-founders Dr. Evan Unger (Executive Chairman, recognized with the 2024 Harry Fischer Award for Excellence in Contrast Media Research) and Dr. Jennifer LH Johnson (COO), with Rong Wang as President and CEO and Wilson W. Cheung, CPA, joining as an Independent Board Member in September 2025.

NuvOx Therapeutics firmographics

Firmographics
Name
NuvOx Therapeutics
Legal name
NuvOx Therapeutics, Inc.
Website
https://nuvoxtherapeutics.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
NuvOx Therapeutics is a privately held, clinical-stage biopharmaceutical company developing NanO2 (DDFPe), an intravenous perfluorocarbon oxygen therapeutic designed to reverse tissue hypoxia in glioblastoma, stroke, respiratory distress, myocardial infarction, sickle cell anemia and related indications, currently advancing multiple Phase Ib/IIb trials funded by grants and convertible notes.
Ownership category
akta.pro rank

NuvOx Therapeutics industry classification

Industry
Product category
Oxygen Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Oxygen therapeutics
  • Perfluorocarbon emulsion
  • Tissue hypoxia treatment
  • Radiosensitizer therapy
  • Clinical stage biopharmaceutical

Where NuvOx Therapeutics is headquartered

Location

Headquarters

HQ city
Tucson
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NuvOx Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Convertible notes financing: Pre-revenue clinical-stage company; in 2023 closed an oversubscribed convertible notes round raising approximately $7 million, exceeding an initial $5 million goal, to fund Phase IIb and Phase Ib trials.
  2. Exempt securities offering (Form D): Filing of SEC Form D indicating an exempt securities offering valued at $5 million, with $1,050,000 already sold; reflects private placement capital raise typical of pre-commercial biotech.
  3. Government and non-dilutive grant funding: Operations funded largely through grants: $900,000 NIH NINDS grant for SPAN stroke network; approximately $2 million NCI SBIR Direct-to-Phase II grant (with FYR Bio); BARDA contract number 75A50123C00034 (EXTEND respiratory distress trial); UK Efficacy and Mechanism Evaluation (EME) Program funding the NOVEL Phase IIb stroke trial. NanO2 is under clinical investigation and not yet approved for general medical use, so there is no product revenue.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

NuvOx Therapeutics product offering

Product offering

Core offering

NuvOx Therapeutics is developing NanO2 (dodecafluoropentane emulsion / DDFPe), a first-in-class intravenously administered perfluorocarbon-based oxygen therapeutic intended to reverse tissue hypoxia. The same active ingredient is being investigated across multiple indications including glioblastoma, acute ischemic stroke, respiratory distress/ARDS, acute myocardial infarction, sickle cell anemia, hemorrhagic shock, traumatic brain injury, and spinal cord injury. The product is currently in clinical development (Phase Ib through Phase IIb) and is not yet approved for general medical use.

Differentiator

Problem solved

Functional benefit

Brands

  • NanO₂ (NanO₂™): Lead investigational oxygen therapeutic product candidate of NuvOx; dodecafluoropentane emulsion (DDFPe) designed to enhance oxygen delivery from lungs to blood and from blood to hypoxic tissue. Tested in 7+ indications with safety data in approximately 2,000 subjects.

Products and services

  • NanO2 (DDFPe / dodecafluoropentane emulsion) First-in-class, investigational, intravenously administered perfluorocarbon-based oxygen therapeutic designed to improve the flow of oxygen from lungs to blood and from blood to tissue, reversing tissue hypoxia. Tested in 7+ indications with safety data in approximately 2,000 subjects. Currently under clinical investigation and not yet approved for general medical use.

Quantifiable outcome

  • Preclinical stroke: 71%–87% mean reduction in infarct volumes (rabbit model)
  • +7 more outcomes

Companies that use NuvOx Therapeutics

Customer profile

Named customers7 records

Segments7 records

Ideal customer profiles4 records

NuvOx Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

NuvOx Therapeutics partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

  • U.S. Department of Veteran Affairs (VA)coreStrategic or Co-development Partner · 22 April 2026NuvOx entered into a research collaboration agreement with the Department of Veteran Affairs to investigate NanO2 in animal models of spinal cord injury. Project led by Dr. Prodip Bose (Director, MRI/PET, and Translational Neurotrauma Rehabilitation Laboratory, Malcom Randall VA Medical Center, North Florida/South Georgia VA Health System).
  • George Washington University (Dr. Pavani Chalasani)coreStrategic or Co-development Partner · 24 November 2025Researchers at the GW University Cancer Center, in collaboration with NuvOx, have demonstrated that NanO2 boosts immunotherapy response in Triple Negative Breast Cancer; two abstracts accepted at prestigious conventions in November 2025.
  • FYR BioflagshipStrategic or Co-development Partner · 19 November 2025FYR Bio and NuvOx Therapeutics are collaborating on liquid-biopsy integration into NuvOx's Phase IIb glioblastoma trial. The partnership is supported by a nearly $2 million Direct-to-Phase II SBIR grant from the US National Cancer Institute (announced September 26, 2025; press release November 19, 2025) to identify biomarkers of glioblastoma progression and treatment response using FYR's EV-based liquid biopsy technology.
  • University of Texas at Houston (Dr. Sunil Krishnan)coreStrategic or Co-development PartnerDr. Sunil Krishnan serves as lead Principal Investigator of the REBORN Phase II trial (Radiation Enhancement with Bevacizumab, Lomustine, Oxygen Replenishment, and NanO2 [DDFPe] in Recurrent Gliomas) for recurrent high-grade gliomas, FDA-authorized March 4, 2026.
  • Center for Neurosciences (Tucson, AZ)minorImplementation/ SI/ Consulting PartnerSite where the first FDA-authorized single-patient Expanded Access treatment of NanO2 for newly diagnosed glioblastoma was administered by Dr. Michael Badruddoja and Dr. Matthew McFarlane on March 10, 2026. Center for Neurosciences is Southern Arizona's largest and longest-standing neuroscience medical practice.
  • Covenant Health / Grey Nuns Community Hospital (Edmonton, Alberta)coreImplementation/ SI/ Consulting PartnerCovenant Health is one of Canada's largest Catholic healthcare organizations. Grey Nuns Community Hospital is the EXTEND-1b trial site with Dr. Senaratne as Principal Investigator; enrolled 6 patients per cohort and observed statistically significant improvement in arterial oxygenation.
  • Health CanadacoreOthersHealth Canada authorized the EXTEND Phase Ib respiratory distress trial (June 30, 2024) and the subsequent Phase II trial in moderate-to-severe respiratory distress.
  • Medicines and Healthcare products Regulatory Agency (MHRA, UK)coreOthersUK MHRA approved NuvOx to commence the Phase IIb NOVEL stroke trial (announced January 21, 2025).
  • University of Arizona College of Medicine – PhoenixminorGTM or Marketing PartnerNuvOx Therapeutics executives participated as external biotech industry presenters at the Second Annual Research Week (April 29 – May 5, 2026), which drew a record 793 total attendees.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

NuvOx Therapeutics competitors and assessment

Company assessment

Direct peers

  • Diffusion Pharmaceuticals: Developed trans sodium crocetinate (TSC), an oxygen diffusion enhancer targeting the same hypoxia-driven indications as NanO2 including glioblastoma, stroke, and respiratory distress. NuvOx is widely cited as the most effective of 74 clinical-stage oxygen therapeutic compounds, positioning Diffusion as the most directly comparable peer in the oxygen therapeutic category.
  • Tenax Therapeutics: Clinical-stage company developing therapies for cardiopulmonary conditions, including hypoxemic respiratory failure and pulmonary hypertension. Overlaps with NuvOx's EXTEND respiratory distress/ARDS program on oxygen delivery and hypoxia-related cardiopulmonary indications.
  • Athersys: Developed MultiStem cell therapy for stroke and ARDS — two of NuvOx's lead indications. Comparable in clinical stage, multi-indication positioning, and reliance on government/academic collaborations to advance pivotal trials.

Emerging players

  • Kazia Therapeutics: Clinical-stage oncology company developing paxalisib for glioblastoma. Competes for the same GBM patients, investigators, and clinical sites as NuvOx's RESTORE and REBORN trials.
  • CNS Pharmaceuticals: Clinical-stage company developing berubicin for recurrent glioblastoma. Directly comparable in trial design (recurrent high-grade glioma) and patient population to NuvOx's REBORN trial.
  • Moleculin Biotech: Clinical-stage oncology company developing WP1066 and other hypoxia- and immune-modulating compounds. Comparable in targeting tumor microenvironment and the same grant-driven, investigator-collaborative development model.
  • PharmaCyte Biotech: Clinical-stage company developing encapsulated cell therapies for solid tumors including pancreatic cancer. Comparable in pre-revenue, clinical-stage oncology positioning and reliance on academic/clinical collaborations.

Broad incumbents

  • NovoCure: Commercial-stage medical device company with FDA-approved Tumor Treating Fields (Optune) for newly diagnosed and recurrent glioblastoma. Represents the established standard-of-care alternative for the lead indication of NuvOx's RESTORE trial.
  • Bristol-Myers Squibb: Manufactures lomustine (Gleostine), a chemotherapy backbone in NuvOx's REBORN trial for recurrent high-grade glioma. As a large oncology incumbent, Bristol-Myers Squibb is a potential strategic acquirer or combination partner.
  • Penumbra: Commercial-stage company specializing in stroke intervention devices (thrombectomy, aspiration). Represents the established mechanical standard of care in large vessel occlusion stroke, which NanO2 is positioned to complement in the NOVEL Phase IIb trial.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NuvOx Therapeutics social profiles

Digital presence

NuvOx Therapeutics compliance and trust

Trust signal

Compliance6 records

NuvOx Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NuvOx Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

NuvOx Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NuvOx Therapeutics funding detail

Funding detail

Funding overview

Funding rounds23 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NuvOx Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NuvOx Therapeutics

What does NuvOx Therapeutics do?

NuvOx Therapeutics is developing NanO2 (dodecafluoropentane emulsion / DDFPe), a first-in-class intravenously administered perfluorocarbon-based oxygen therapeutic intended to reverse tissue hypoxia. The same active ingredient is being investigated across multiple indications including glioblastoma, acute ischemic stroke, respiratory distress/ARDS, acute myocardial infarction, sickle cell anemia, hemorrhagic shock, traumatic brain injury, and spinal cord injury. The product is currently in clinical development (Phase Ib through Phase IIb) and is not yet approved for general medical use.

Is NuvOx Therapeutics a public or private company?

NuvOx Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was NuvOx Therapeutics founded?

NuvOx Therapeutics was founded in 2008. It employs 11 to 50 people.

Where is NuvOx Therapeutics based?

NuvOx Therapeutics is headquartered in Tucson, United States, in the North America region.

How does NuvOx Therapeutics make money?

Three revenue lines are on record. Convertible notes financing is the primary driver. The others are exempt securities offering (Form D) and government and non-dilutive grant funding.

Who are NuvOx Therapeutics's main competitors?

Direct peers on record are Diffusion Pharmaceuticals, Tenax Therapeutics and Athersys. Emerging players are Kazia Therapeutics, CNS Pharmaceuticals, Moleculin Biotech and PharmaCyte Biotech. Broad incumbents are NovoCure, Bristol-Myers Squibb and Penumbra.

Does NuvOx Therapeutics have an API?

No public API is recorded for NuvOx Therapeutics.

What industry is NuvOx Therapeutics in?

NuvOx Therapeutics's product category is Oxygen Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsNuVox Therapeutics plans $20M IPO on NYSENuVox Therapeutics, a Tucson-based biotech company developing oxygen therapeutics to treat hypoxia, is planning to raise as much as $20 million through an initial public offering on the NYSE. The article appears to be truncated, with the remainder of the content reserved for subscribers.American City Business JournalsNuVox Therapeutics plans $20M IPO on NYSENuVox Therapeutics, a Tucson-based biotech, plans to raise up to $20 million in an initial public offering on the NYSE. The company develops oxygen therapeutics to treat hypoxia.AInvestNuvOx's $20M IPO Looks Small-Risk-But a $98M Biotech Bet Still Needs One Big WinNuvOx filed to raise up to $20 million through an IPO of 2.86 million shares priced at $6.00 to $8.00, with ThinkEquity leading the book, valuing the company at approximately $98 million fully diluted on a post-money basis. The clinical-stage biotech's lead asset NanO2, an intravenous oxygen therapeutic, has completed Phase Ib/IIa trials for stroke and glioblastoma, with a U.S. Phase IIb GBM study having completed enrollment and a UK Phase IIb stroke trial underway. The article presents a binary risk profile for investors: no products based on NanO2 have received regulatory approval, the company had only $1 million in revenue over the trailing twelve months, and the $20 million capital raise leaves limited room for trial delays before data readouts.Investing.comNuvOx Therapeutics files for IPO on NYSE American By Investing.comNuvOx Therapeutics, Inc. has filed for an initial public offering of common stock on NYSE American, with a price range of $6.00 to $8.00 per share and ticker symbol NUOX. ThinkEquity is serving as the underwriter for the offering, which is pending final approval from the exchange. Prior to this offering, there has been no public market for NuvOx Therapeutics common stock.TradingViewNuvOx Therapeutics, Clinical-Stage Oxygen Therapeutics Developer, Files for NYSE American IPONuvOx Therapeutics, a clinical-stage biopharmaceutical company developing oxygen therapeutics for conditions including acute ischemic stroke, glioblastoma multiforme, and acute respiratory distress syndrome, filed for an initial public offering on the NYSE American under the ticker NUOX, offering 2,860,000 shares at $6.00 to $8.00 per share with ThinkEquity as representative of the underwriters. The company plans to use approximately $5.0 million of proceeds to complete its Phase IIb GBM trial, $6.0 million for Phase II ARDS trials, and additional funds for stroke trial supply and Phase III GBM preparation. NuvOx has completed Phase Ib/IIa trials in stroke and GBM, holds Orphan Drug Designation for GBM and sickle cell disease, and has Fast Track designation for stroke, while reporting FY2025 revenue of $0.98 million primarily from grants against a net loss of $16.59 million.Renaissance CapitalHypoxia-focused biotech NuvOx Therapeutics files for a $20 million IPONuvOx Therapeutics, a clinical-stage biopharmaceutical company based in Tucson, Arizona, filed on July 17, 2026 with the SEC to raise up to $20 million in an initial public offering, offering 2.9 million shares at a price range of $6 to $8 per share. At the midpoint of the proposed range, the company would command a fully diluted market value of $98 million, with the proceeds intended to advance its lead NanO2 program currently in Phase IIb trials for acute ischemic stroke and glioblastoma. The company, founded in 2008, reported $1 million in revenue for the 12 months ended March 31, 2026 and plans to list on NYSE American under the symbol NUOX, with ThinkEquity serving as sole bookrunner.Arizona WETSecond Annual Research Week Celebrates Innovation and CollaborationThe University of Arizona College of Medicine – Phoenix hosted its second annual Research Week from April 29 to May 5, featuring five days of events including Academic Excellence Day, Biomedical Research Day, Research Education and Career Development Day, the Scholarly Project Research Symposium, and the ABRC-Flinn Research Conference. The event drew a record 793 total attendees across all five days, with 245 attendees on the final day, showcasing biomedical research breakthroughs from faculty, students, postdoctoral fellows, and external biotech industry presenters including NuvOx Therapeutics executives.BioSpaceFYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma TrialFYR Bio and NuvOx Therapeutics have been awarded a $1.98 million grant from the National Cancer Institute to collaborate on integrating FYR's liquid-biopsy technology into NuvOx's Phase IIb glioblastoma trial. This partnership aims to use extracellular-vesicle biomarkers to help distinguish pseudoprogression from true tumor progression during treatment with NuvOx's NanO₂ radiosensitizer. The initiative is designed to de-risk NuvOx's clinical development program and refine future trial strategies.FyrFYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma TrialFYR Bio announced a collaboration with NuvOx Therapeutics backed by a two-year $1,976,897 Direct-to-Phase II SBIR grant from the National Cancer Institute to integrate liquid-biopsy technology into NuvOx's Phase IIb glioblastoma trial. The funding will support FYR's EV-Omics platform in analyzing blood samples from NuvOx's RESTORE trial to discover hypoxia-related biomarkers that could differentiate pseudoprogression from true tumor progression. This collaboration aims to de-risk NuvOx's clinical development and inform future trial design and patient selection strategies.